RT Journal Article
SR Electronic
T1 The Cognitive Connectome in Dementia with Lewy Bodies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.11.14.23298515
DO 10.1101/2023.11.14.23298515
A1 Yánez-Pérez, Roraima
A1 García-Cabello, Eloy
A1 Habich, Annegret
A1 Cedres, Nira
A1 Diaz-Galvan, Patricia
A1 Abdelnour, Carla
A1 Toledo, Jon B.
A1 Barroso, José
A1 Ferreira, Daniel
YR 2023
UL http://medrxiv.org/content/early/2023/11/15/2023.11.14.23298515.abstract
AB Objectives Cognition plays a central role for diagnosing and characterizing dementia with Lewy bodies (DLB). However, the complex associations among cognitive functions are largely unknown in DLB. To fill this gap, we compared the cognitive connectome of DLB patients, healthy controls (HC) and patients with Alzheimer’s disease (AD).Methods We obtained data from the National Alzheimer’s Coordinating Center (NIA/NIH Grant U24-AG072122). We built separate cognitive connectomes for DLB (n=104), HC (n= 3703), and AD (n=1985) groups using pairwise correlations between 24 cognitive variables mapping multiple cognitive functions. The cognitive connectomes in DLB, HC, and AD groups were compared using standard global and nodal graph measures of centrality, integration, and segregation.Results In global connectome measures, DLB patients showed a higher global efficiency (integration) and lower transitivity (segregation) than HCs and AD. Nodal connectome measures showed a higher global efficiency in most cognitive functions in DLB compared to HCs. Additionally, we found a lower local efficiency (segregation) and nodal strength (centrality) in memory variables and a higher participation coefficient in executive variables (centrality) in DLB compared with both HCs and AD.Conclusions The cognitive connectome in DLB showed a signature dedifferentiation pattern of aberrant correlations. Executive, processing speed and attention functions played a central role in the cognitive connectome of DLB patients. Furthermore, the role of executive and memory functions in the cognitive connectome distinguished DLB and AD patients. These findings may help advance our understanding of the clinical phenotype in DLB, and continue to improve the challenging differential diagnosis between DLB and AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Swedish Research Council (Vetenskapsrådet, grant 2022-00916), the Center for Innovative Medicina (CIMED, grants 20200505 and FoUI-988826), the regional agreement on medical training and clinical research of Stockholm Region (ALF Medicine, grants FoUI-962240 and FoUI-987534), the Swedish Brain Foundation (Hjärnfonden FO2023-0261, FO2022-0175, FO2021-0131), the Swedish Alzheimer Foundation (Alzheimerfonden AF-968032, AF-980580), the Swedish Dementia Foundation (Demensfonden), the Gamla Tjänarinnor Foundation, the Gun och Bertil Stohnes Foundation, Funding for Research from Karolinska Institutet, Neurofonden, the Foundation for Geriatric Diseases at Karolinska Institutet, and a research fellowship from Government of Canary Islands (call year 2021; TESIS2021010091) co-financed by the Canary Islands Regional Ministry of Economy, Industry, Trade and Knowledge's Research, Innovation and Information Society Agency and by the European Social Fund (ESF) Integrated Operational Programme of the Canary Islands 2014-2020, Axis 3 Priority Theme 74 (85%). Data used in this study were obtained from the National Alzheimer's Coordinating Center (NACC) database. The NACC database is funded by NIA/NIH Grant U24 AG072122. NACC data are contributed by the NIA-funded ADRCs: P30 AG062429 (PI James Brewer, MD, PhD), P30 AG066468 (PI Oscar Lopez, MD), P30 AG062421 (PI Bradley Hyman, MD, PhD), P30 AG066509 (PI Thomas Grabowski, MD), P30 AG066514 (PI Mary Sano, PhD), P30 AG066530 (PI Helena Chui, MD), P30 AG066507 (PI Marilyn Albert, PhD), P30 AG066444 (PI John Morris, MD), P30 AG066518 (PI Jeffrey Kaye, MD), P30 AG066512 (PI Thomas Wisniewski, MD), P30 AG066462 (PI Scott Small, MD), P30 AG072979 (PI David Wolk, MD), P30 AG072972 (PI Charles DeCarli, MD), P30 AG072976 (PI Andrew Saykin, PsyD), P30 AG072975 (PI David Bennett, MD), P30 AG072978 (PI Neil Kowall, MD), P30 AG072977 (PI Robert Vassar, PhD), P30 AG066519 (PI Frank LaFerla, PhD), P30 AG062677 (PI Ronald Petersen, MD, PhD), P30 AG079280 (PI Eric Reiman, MD), P30 AG062422 (PI Gil Rabinovici, MD), P30 AG066511 (PI Allan Levey, MD, PhD), P30 AG072946 (PI Linda Van Eldik, PhD), P30 AG062715 (PI Sanjay Asthana, MD, FRCP), P30 AG072973 (PI Russell Swerdlow, MD), P30 AG066506 (PI Todd Golde, MD, PhD), P30 AG066508 (PI Stephen Strittmatter, MD, PhD), P30 AG066515 (PI Victor Henderson, MD, MS), P30 AG072947 (PI Suzanne Craft, PhD), P30 AG072931 (PI Henry Paulson, MD, PhD), P30 AG066546 (PI Sudha Seshadri, MD), P20 AG068024 (PI Erik Roberson, MD, PhD), P20 AG068053 (PI Justin Miller, PhD), P20 AG068077 (PI Gary Rosenberg, MD), P20 AG068082 (PI Angela Jefferson, PhD), P30 AG072958 (PI Heather Whitson, MD), P30 AG072959 (PI James Leverenz, MD). JBT is the Ann and Billy Harrison Centennial Chair in Alzheimer's Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institution Review Board of Alzheimer's Disease Research Centers included in the National Alzheimer's Coordinating Center database gave ethical approval for scientific works derived from the use of data in the National Alzheimer's Coordinating Center database.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in this study are available at NACC webpage under request: https://naccdata.org/